alpha(4)beta(1) and alpha(4)beta(7)
integrins are preferentially expressed on eosinophils and mononuclear leukocytes and play critical roles in their recruitment to inflammatory sites. We investigated the effects of
TR14035, a small molecule, alpha(4)beta(1)/alpha(4)beta(7) dual antagonist, in a rat model of allergic
asthma. Actively sensitized rats were challenged with
aerosol antigen or saline on day 21, and the responses evaluated 24 and 48-h later.
TR14035 (3 mg kg(-1), p.o.) was given 1-h before and 4-h after
antigen or saline challenge.
Airway hyper-responsiveness to intravenous
5-hydroxytryptamine was suppressed in TR14035-treated rats. Eosinophil, mononuclear cell and neutrophil counts, and
eosinophil peroxidase and
protein content in the bronchoalveolar lavage fluid (BALF) were decreased in TR14035-treated rats. Histological study showed a marked reduction of lung inflammatory lesions by
TR14035. At 24-h postchallenge,
antigen-induced lung
interleukin (IL)-5
mRNA upregulation was suppressed in TR14035-treated rats. By contrast,
IL-4 levels in BALF were not significantly affected by
TR14035 treatment.
IL-4 selectively upregulates
vascular cell adhesion molecule-1 (VCAM-1), which is the main endothelial
ligand of alpha(4)
integrins. Intravital microscopy within the rat mesenteric microcirculation showed that 24-h exposure to 1 microg per rat of
IL-4 induced a significant increase in leukocyte rolling flux, adhesion and emigration. These responses were decreased by 48, 100 and 99%, respectively in animals treated with
TR14035. In conclusion,
TR14035, by acting on alpha(4)beta(1) and alpha(4)beta(7)
integrins, is an orally active inhibitor of airway leukocyte recruitment and hyper-responsiveness in animal models with potential interest for the treatment of
asthma.